Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2025-03-13 AGM Information
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于股东大会开设网络投票提示服务的公告
AGM Information Classification · 90% confidence The document is a short announcement (795 characters) about the company's shareholder meeting voting service, specifically about the provision of a network voting reminder service for the upcoming 2024 Annual General Meeting (AGM). It references the AGM date and related prior announcements but does not contain any financial data, meeting materials, or voting results. It is not the AGM materials themselves but an announcement related to the AGM process. Therefore, it fits best under AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related announcements about the AGM process.
2025-03-13 Chinese
天士力2024年年度股东大会会议资料
AGM Information Classification · 95% confidence The document is titled '2024 年年度股东大会会议资料' which translates to '2024 Annual General Meeting (AGM) Meeting Materials'. It contains detailed agenda items for the 2024 AGM, including reports such as the Board of Directors' work report, Supervisory Board report, financial statements, profit distribution plan, and the full 2024 Annual Report text and summary. It also includes voting procedures, attendance details, and legal opinions related to the AGM. The content is consistent with materials prepared and shared for an Annual General Meeting rather than the Annual Report itself or other filings. The document length is substantial (15,000 characters), indicating it is the meeting materials, not just a brief announcement. Therefore, the document fits the category of AGM Information (AGM-R).
2025-03-07 Chinese
天士力关于2024年年度股东大会增加临时提案的公告
AGM Information Classification · 95% confidence The document is an announcement regarding the addition of a temporary proposal to the 2024 Annual General Meeting (AGM) of TianShiLi Pharmaceutical Group Co., Ltd. It includes details about the AGM date, voting procedures, and the agenda items to be discussed, including the temporary proposal. The document does not contain the actual AGM materials or reports but rather informs shareholders about the meeting and the new proposal. The document length is 2497 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or announcements related to it.
2025-03-07 Chinese
简式权益变动报告书（修订稿）（国新投资有限公司）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书（修订稿）" which translates to a "Simplified Equity Change Report (Revised)". It details the change in shareholding of 国新投资有限公司 in 天士力医药集团股份有限公司, including the number of shares acquired, the nature of the transaction (agreement transfer), the price, payment terms, and related agreements. It also includes disclosures about the information disclosure obligations, legal compliance, and other related information. The document is focused on reporting a change in major shareholding and the related transaction details. There is no indication that this is an annual report, earnings release, or any other type of report. It is clearly a notification of a significant shareholding change, consistent with the definition of Major Shareholding Notification (MRQ). The document length (over 12,000 characters) and detailed content confirm it is the report itself, not just an announcement of a report publication or a certification. Therefore, the correct classification is Major Shareholding Notification (MRQ).
2025-02-28 Chinese
华泰联合证券有限责任公司关于天士力医药集团股份有限公司详式权益变动报告书（修订稿）之财务顾问核查意见
Regulatory Filings
2025-02-28 Chinese
天士力关于控股股东及其一致行动人签署《股份转让协议之补充协议》的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of supplementary agreements to share transfer agreements involving the controlling shareholder and related parties of the company. It details changes in shareholding, governance structure, and related transaction terms. The content focuses on share transfer agreements, control changes, and related disclosures rather than financial results, audit opinions, or regulatory certifications. It is not a full financial report, earnings release, or management discussion. The document is a formal announcement of a capital/ownership change event, specifically about share transfer agreements and control changes. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3347 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is CAP with high confidence.
2025-02-28 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.